Oct 25, 2026 03:30AM
Oct 24, 2026 02:30AM
Oct 22, 2026 02:27PM
Oct 20, 2026 07:50AM
Oct 18, 2026 06:05PM
Oct 9, 2026 06:45AM
Oct 9, 2026 06:45AM New Phase 3b data on Lilly's Taltz (ixekizumab) and Zepbound (tirzepatide) advance understanding of the interconnected immune and metabolic biology in adults with psoriasis and obesity
Oct 6, 2026 09:06AM
Oct 5, 2026 07:50AM
Oct 5, 2026 07:50AM
Oct 2, 2026 03:06PM
Oct 2, 2026 03:05PM
Oct 1, 2026 07:01AM
Oct 1, 2026 07:00AM Lilly's oral GLP-1, Foundayo (orforglipron), was associated with significant reductions in predicted long-term risk of type 2 diabetes and cardiovascular disease
Sep 30, 2026 06:05PM
Sep 30, 2026 06:00PM
Sep 30, 2026 10:22AM
Sep 30, 2026 10:15AM
Sep 30, 2026 10:15AM
Sep 30, 2026 08:05AM
Sep 30, 2026 08:03AM New Phase 3b data show Lilly's EBGLYSS (lebrikizumab-lbkz) delivered significant and rapid improvements in skin clearance, itch, pain, and patient satisfaction in people with moderate-to-severe hand a
Sep 29, 2026 06:00PM
Sep 29, 2026 07:01AM
Sep 29, 2026 07:00AM
Sep 29, 2026 06:03AM
Sep 29, 2026 03:00AM
Sep 28, 2026 06:45AM
Sep 28, 2026 06:45AM Lilly launches the Lilly Change the Course Commitment, aiming to address treatment gaps in diabetes and obesity in LMICs
Sep 25, 2026 05:12PM
Sep 25, 2026 05:11PM
Sep 24, 2026 06:46AM
Sep 24, 2026 06:45AM
Sep 21, 2026 05:50PM
Sep 21, 2026 05:40PM
Sep 18, 2026 01:54PM FDA approves Lilly's Inluriyo combo with Verzenio for breast cancer
Sep 18, 2026 01:54PM
Sep 15, 2026 06:45AM
Sep 15, 2026 06:45AM
Aug 31, 2026 07:01AM
Aug 31, 2026 07:00AM
Aug 28, 2026 07:00AM
Aug 28, 2026 07:00AM FDA approves Lilly's Mounjaro (tirzepatide) to reduce cardiovascular risk in adults with type 2 diabetes
Aug 26, 2026 06:45AM
Aug 26, 2026 06:45AM
Aug 18, 2026 12:57PM
Aug 12, 2026 09:15AM
Aug 12, 2026 05:57AM
Aug 12, 2026 05:30AM
Aug 5, 2026 06:45AM Lilly reports second-quarter 2026 financial results, raises full-year guidance, and highlights continued growth and pipeline progress
Aug 3, 2026 07:45AM

335,220 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All